Idexx LaboratoriesIDXX
Recorded

Idexx Laboratories 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration57 minParticipants10

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good morning, and welcome to the IDEXX Laboratories Third Quarter 2026 Earnings Conference Call. As a reminder, today's conference is being recorded. Participating in the call this morning are Mike Erickson, President and Chief Executive Officer, Andrew Emerson, Chief Financial Officer, and John Ravis, Vice President, Investor Relations. IDEXX would like to preface the discussion today with a caution regarding forward-looking statements. Listeners are reminded that our discussion during the call will include forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed today. Additional information regarding these risks and uncertainties is available under the forward-looking statements notice in our press release issued this morning, as well as in our periodic filings with the Securities and Exchange Commission, which can be obtained from the SEC or by visiting the Investor Relations section of our website, idexx.com.

Operator

During this call, we will be discussing certain financial measures not prepared in accordance with generally accepted accounting principles, or GAAP. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures is provided in our earnings release, which may also be found by visiting the Investor Relations section of our website. In reviewing our third quarter 2026 results and updated 2026 guidance, please note all references to growth, organic growth, and comparable growth refer to growth compared to the equivalent prior year period, unless otherwise noted. To allow broad participation in the Q&A, we ask that each participant limit their questions to one, with one follow-up as necessary. We appreciate you may have additional questions, so please feel free to get back into the queue, and if time permits, we'll take your additional questions.

Operator

Today's prepared remarks will be posted to the Investor Relations section of our website after the earnings conference call concludes. I would now like to turn the call over to Andrew Emerson.

Andrew EmersonCFO

Good morning. I'm pleased to take you through our third quarter results and provide an updated outlook for our full year 2026 financial expectations. During the third quarter, IDEXX delivered outstanding financial results, driven by strong global execution, the expanding impact of IDEXX Innovations, and continued progress in increasing the medically relevant use of diagnostics across our companion animal business. We also advanced our software, data, and AI capabilities through the acquisition of CoVet. Revenue increased 10% organically, supported by 11% organic growth in CAG Diagnostics recurring revenues, reflecting nearly 14% gains in international regions and nearly 10% growth in the U.S. We see strong demand for diagnostic solutions, including IDEXX Innovations, as demonstrated with premium instrument placements of nearly 5,800 units, with over 1,900 IDEXX inVue Dx analyzers.

Andrew EmersonCFO

Operating performance was excellent, with comparable operating margin gains of approximately 60 basis points year-over-year, led by improvement in gross margin while making ongoing investments in the business, including costs related to the CoVet acquisition. Strong operating profit gains enabled earnings per share of $4.01 in the quarter, an increase of 18% as reported and 22% on a comparable basis. Strong third quarter performance supports an increase to our full year revenue outlook. We are raising our full year revenue range to $4,741 million-$4,767 million, an increase of $32 million at midpoint, reflecting strong third quarter performance and approximately $5 million of revenue from CoVet. Our updated full year overall organic revenue growth outlook is 9.3%-10%, with organic CAG Diagnostics recurring revenue growth of 10.3%-11%.

Andrew EmersonCFO

These ranges represent an increase of approximately 60 basis points at midpoint, along with tightening the low end of the range as we enter the final quarter of the year. We also increased our full year EPS outlook to $14.96-$15.16 per share, an increase of $0.25 per share at midpoint, reflecting 15%-16% comparable EPS growth while absorbing near-term dilution related to the CoVet acquisition. We will provide further details on our updated 2026 financial expectations later in my comments. Let's begin with a review of our third quarter results. Third quarter organic revenue growth of 10% was driven by 10% CAG revenue gains, 8% growth in our water business, and 3% growth in LPD.

Andrew EmersonCFO

Strong CAG results were driven by CAG Diagnostics recurring revenue growth of 11% organically, which was volume-led, reflecting strong execution and contributions from innovations, and included approximately 4% global net price improvement. Demand for IDEXX diagnostic solutions remains high, and we have realized benefits from net new customer gains, expansion of our premium instrument install base, and increased utilization of IDEXX innovations. U.S. organic CAG Diagnostics recurring revenue grew 9.6% in Q3, with solid volume gains and net price realization aligned with our full year expectations. U.S. growth continues to be supported by greater testing frequency and intensity per visit as customers adopt our expanded menu. U.S. same-store clinical visits declined an estimated 1.8% in the quarter, reflecting a U.S. CAG Diagnostics recurring revenue growth premium of approximately 1,100 basis points, our fourth consecutive quarter above 1,000 basis points. Underlying patient dynamics continue to support long-term demand for diagnostics.

Andrew EmersonCFO

In the quarter, pets age 5+ years, where diagnostic frequency rises, contributed to clinical visit growth. With a substantial majority of wellness visits still not including blood work, increased diagnostic inclusion remains a long-duration growth lever that does not depend on visit growth. International CAG Diagnostics recurring revenues grew 14% organically in Q3, with double-digit gains across major international regions. International performance reflects the success of our strategic focus on developing the sector and strong IDEXX execution. We are also encouraged by the quality of growth reflected by the strong momentum in net new customers and same-store sales gains. We have successfully completed expansions highlighted on the second-quarter call well ahead of schedule. IDEXX innovation and commercial execution drove strong organic revenue gains across our major testing modalities globally in the quarter.

Andrew EmersonCFO

IDEXX VetLab consumable revenues increased 15% on an organic basis, reflecting double-digit growth in both the U.S. and international regions. Consumables growth was supported by the expansion of our premium instrument install base and broader menu utilization. We benefited from ongoing growth of Catalyst Pancreatic Lipase, Catalyst Cortisol, and SDMA inclusion in chemistry runs following the integration of SDMA into our chemistry CLIPs. inVue Dx recurring revenue continues to ramp, aided by the expanding install base and broadening of FNA on the platform. We remain in our estimated range of 3,500 to 5,500 of recurring revenue per analyzer, while making fine-needle aspirate testing with canine mast cell tumor detection available across all North America customers at the beginning of Q4. Premium instrument placements reached 5,780 units in the quarter, and placement quality remained high.

Andrew EmersonCFO

Globally, we placed 1,904 inVue Dx instruments, with strong international demand and nearly 1,200 competitive and greenfield Catalyst placements globally, with over 300 in the U.S. IDEXX global RefLab revenues increased 10% organically in Q3, led by volume gains from net new customers, including competitive lab wins in the U.S., and increased same-store utilization as customers adopt broader testing menu. The IDEXX Cancer Dx customer base continued to expand, with nearly a quarter of customers ordering in Q3 representing non-primary IDEXX RefLab accounts. With the addition of canine mast cell tumor detection to the panel in late September, we have meaningfully increased the medical value to customers without increasing our price on the panel. Global rapid assay revenues increased 1% organically in Q3, sustaining modest growth seen during Q2.

Andrew EmersonCFO

Veterinary software and diagnostic imaging organic revenues increased 10%, driven by recurring revenue growth and strong placements of our ImageVue DR50 Plus platform, including another record quarter of installations in the U.S. Our cloud-native PIMS footprint continues to expand across both independent and corporate-owned clinics as well. In September, we acquired CoVet, a leading and rapidly growing provider of AI-native ambient listening and clinical workflow software for veterinary practices. The CoVet revenue run rate is approximately $20 million annualized and growing at strong double-digit rates, creating another revenue growth driver for the software modality and opportunity for further supporting diagnostic utilization. Water revenues increased 8% organically in Q3, and livestock, poultry, and dairy revenues increased 3% organically.

Andrew EmersonCFO

Turning to the P&L, strong recurring revenue growth enabled 13% reported operating profit gains, with reported operating margins of 33.1%, up 100 basis points as reported and approximately 60 basis points on a comparable basis, inclusive of CoVet-related costs. Gross profit increased 12% in the quarter as reported, and gross margins were 62.9%, up 110 basis points as reported and 90 basis points on a comparable basis. These gains reflect benefits from strong recurring revenue growth in IDEXX VetLab consumables and RefLab volumes, operational productivity, and favorable product mix, with pricing benefits offsetting inflationary cost pressures. On a reported basis, operating expenses increased 10% year-over-year and 11% on a comparable basis, including CoVet-related costs. We continue to advance investments in our innovation agenda, global commercial expansions, and information technology capabilities.

Andrew EmersonCFO

Q3 EPS was $4.01 per share, an increase of 18% as reported and 22% on a comparable basis. EPS in the quarter included a $0.03 per share benefit related to a $3.5 million non-operating gain on an equity investment, bringing the year-to-date benefit to $0.05 per share, or $4.7 million. Share-based compensation activity benefited the quarter by $0.01 per share, compared to a $0.17 per share benefit in the prior year period, and foreign exchange added $4 million to operating profit and $0.04 to EPS in Q3, net of hedge effects. Free cash flow was $421 million in Q3 and $978 million year to date. On a trailing 12-month basis, our net income to free cash flow conversion rate was 110%.

Andrew EmersonCFO

For the full year, our updated outlook for free cash flow conversion is 95%-100% of net income, including updated full-year capital spending of approximately $160 million. Our balance sheet remains strong. Total debt was aligned with prior year-end as strong free cash flow supported repaying $75 million of senior notes in the quarter, and we deployed approximately $335 million of capital towards the CoVet acquisition and share repurchases in Q3, bringing the year-to-date share repurchases to $805 million and supporting a 2% year-over-year reduction in diluted shares outstanding. Turning to our full year 2026 outlook, as noted, we're increasing our outlook for overall revenue to $4,741 million-$4,767 million, an increase of $32 million at midpoint.

Andrew EmersonCFO

This reflects the flow-through benefits of strong third quarter performance, CoVet revenue, and relatively consistent foreign exchange effects compared to prior estimates. Our reported revenue growth of 10.1%-10.8% includes approximately 70 basis points benefit from foreign exchange at the rates outlined in our press release and approximately $5 million of CoVet revenue in 2026. As a sensitivity, a 1% strengthening of the U.S. dollar would reduce revenue by approximately $4 million and EPS by $0.02 per share for the remainder of the year. Our updated overall organic revenue growth outlook of 9.3%-10% includes organic growth range of 10.3%-11% for CAG Diagnostics recurring revenue, including approximately 4% benefit from global net price realization.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day